hat
NCT02695160. Yon Etid Faz I, Open-Etikèt, Dòz Moute Pou Evalye Sekirite ak Tolerabilite AAV2 / 6 Faktè IX Terapi Jen Genyen Atravè Zin Nuklea Dwèt (ZFN) Entèmedyè ki se Medyatè Sible SB-FIX nan sijè pou granmoun ki gen emofil grav B. https://clinicaltrials.gov/ct2/show/NCT02695160
eng
NCT02695160. A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B. https://clinicaltrials.gov/ct2/show/NCT02695160